Treatment With Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

  • End date
    Mar 1, 2027
  • participants needed
  • sponsor
    James J. Peters Veterans Affairs Medical Center
Updated on 21 April 2022
spinal cord
bone mineral density
spinal cord disorder
spinal cord injury


The objective of the proposed work is to determine whether administration for 12 months of romosozumab (evenity) followed by 12 months of denosumab (prolia) will maintain bone mass at the knee in subjects with chronic SCI.


The purpose of this study is to address the gap in the treatment of osteoporosis in individuals with chronic SCI by partially restoring BMD with romosozumab treatment for 12 months and then to maintain, or further increase, BMD with denosumab treatment for 12 months. A two group, randomized, double-blind, placebo-controlled clinical trial will be conducted in 39 participants who have chronic (3-15 years), motor-complete or incomplete SCI and areal BMD (aBMD) values at the distal femur of at the distal femur ≥0.6 g/cm2 but ≤1.0 g/cm2 measured by dual photon X-ray absorptiometry (DXA). The intervention group will receive 12 months of romosozumab followed by 12 months of denosumab, and the control group will receive 12 months of placebo followed by 12 months denosumab

Condition Osteoporosis, Spinal Cord Injuries
Treatment Placebo, Denosumab, Prolia, Evenity, Romoszumab
Clinical Study IdentifierNCT05180032
SponsorJames J. Peters Veterans Affairs Medical Center
Last Modified on21 April 2022


Yes No Not Sure

Inclusion Criteria

) Motor complete or incomplete SCI C4 and below {upper motor lesions; International Standards for Neurological Classification of Spinal Cord Injury (ISNSCI) grade A-C (wheelchair dependent greater than 75% of the time)
) Duration of SCI between 3-15 years
) Males and females (premenopausal) between the ages of 18 and 50 years old (the upper age limit is to reduce the influence of age on the ability of the skeleton to respond to pharmacologic stimulation)
) aBMD at the distal femur greater than or equal to 0.6 g/cm2 but less than or equal to 1.0 g/cm2
) Agreement to use a highly effective contraceptive method for women of reproductive potential

Exclusion Criteria

) Active and/or history of coronary heart disease or stroke
) Bone cancer
) Long-bone fracture of the leg within the past year
) History of prior bone disease [for example Paget's hyperparathyroidism (overproduction of a steroid hormone known as the parathyroid hormone), osteoporosis, etc.]
) Postmenopausal women
) Men with known low functioning testes before SCI
) Medication designed to increase bone density longer than six months after duration of SCI
) As determined by study staff review of my medication, glucocorticoid (anti-inflammatory medications) administration longer than three months duration within the last year
) Endocrinopathies such as the following: hyperthyroidism (overproduction of a hormone known as thyroxine by the thyroid gland in the neck), Cushing's disease or syndrome (excess production of the steroid hormone cortisol), etc
) Severe underlying chronic disease [for example chronic obstructive pulmonary (lung) disease (COPD, end-stage heart disease, chronic renal (kidney) failure]
) Heterotopic ossification (HO- an abnormal growth of bone that can occur after SCI) at the distal femur (the distal femur is the primary outcome variable; HO to any other boney region will not prevent study participation)
) As determined by study staff review of my medication, prescribed a bisphosphonate for heterotopic ossification (HO), or prescribed any other agent to treat osteoporosis other than calcium and vitamin D
) History of chronic alcohol abuse
) Diagnosis of hypercalcemia (excess calcium levels in the blood)
) Diagnosis of hypocalcemia (low calcium levels in the blood). If corrected, subject may still be eligible for study participation)
) Pregnancy, or plans to become pregnant within 6 months after the end of study treatment
) Lactation
) Current diagnosis of cancer or history of cancer within the last 5 years
) As determined by study staff review of my medication, prescribed moderate or high dose corticosteroids (>40 mg/d prednisone or an equivalent dose of other corticosteroid medication) for longer than one week, not including drug administered to preserve neurological function at the time of acute SCI
) As determined by study staff review of my medical records, life expectancy less than 5 years
) History of hypersensitivity reaction (including allergic reaction, facial swelling and hives) to any Prolia (denosumab) or Evenity (romosozumab) component
) Currently experiencing a weakened immune system or infection
) Recent fracture or extensive bone trauma
) Osteonecrosis of the jaw (ONJ- deterioration of the jaw bone) or risk for ONJ, such as invasive dental procedures (including tooth extraction, dental implants, oral surgery in the past 6 months), poor oral hygiene, periodontal and/or pre-existing dental disease
) Planned invasive dental procedure over the next two years
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note